Skip to main content
Clinical Trials/NCT07416149
NCT07416149
Recruiting
Not Applicable

Reducing Post-operative Hypoparathyroidism With Probe-based Near Infrared Autofluorescence (NIRAF)- Assisted Total Thyroidectomy Versus Conventional Total Thyroidectomy, a Randomized-controlled Trial

The University of Hong Kong1 site in 1 country210 target enrollmentStarted: September 16, 2025Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Enrollment
210
Locations
1
Primary Endpoint
Rate of significant post-operative hypoparathyroidism (SPH) after total thyroidectomy (in %)

Overview

Brief Summary

This is a prospective, single-blinded, randomized controlled trial to evaluate whether PTeye™ can reduce post-operative hypoparathyroidism (PH). The study will enroll consecutive patients undergoing total thyroidectomy in a teritary endocrine surgery unit in Hong Kong, randomizing them into receiving conventional surgery versus PTeye™-assisted surgery. Subjects will be assigned to the two groups before surgery. Subjects will be under medical care as in usual practice.

Detailed Description

Post-operative hypoparathyroidism (PH) is a debilitating complication following total thyroidectomy. It arises from inadvertent removal or devascularization of the parathyroid glands. From a previous study in Hong Kong and other population-wide series, permanent PH rates could be as high as 11%, and transient PH rates being 30-48%, posing substantial burden on healthcare systems.

Near-infrared autofluorescence (NIRAF) technology has emerged to assist the identification and preservation of parathyroid glands during surgery. This study investigates the probe-based NIRAF device, PTeye™, which emits laser and receives NIR real-time, thereby detecting parathyroid glands by a simple touch of a probe.

A standardized protocol is devised to use PTeye™ for parathyroid identification at the early stage of surgery, in order to avoid devascularization or inadvertent removal of the parathyroids.

This is a prospective, single-blinded, randomized controlled trial to evaluate whether PTeye™ can reduce PH. The study will enroll consecutive patients undergoing total thyroidectomy in a tertiary endocrine surgery unit in Hong Kong. Patients will be randomized to receive conventional surgery or PTeye™-assisted surgery.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Care Provider)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult patients ≥18 years of age
  • Undergoing total thyroidectomy, or completion total thyroidectomy
  • Pre-operative serum adjusted calcium levels within normal ranges

Exclusion Criteria

  • Patients on pre-operative calcium or vitamin D supplements
  • Patients with pre-operative vitamin D deficiency, defined as serum vitamin D\<30nmol/L
  • Patients with untreated primary or secondary hyperparathyroidism
  • Patient with known non-surgical hypoparathyroidism diseases
  • Patients with estimated glomerular filtration rate \<30ml/1.73m2/min, on dialysis, or having a history of kidney transplant

Arms & Interventions

Conventional total thyroidectomy

No Intervention

Total thyroidectomy without PTeye™

Total thyroidectomy with the PTeye™ parathyroid detection system

Active Comparator

PTeye™ assisted total thyroidectomy. PTeye will be used to identify the parathyroid glands early in the course of surgery.

Intervention: PTeye™ parathyroid detection system (Device)

Outcomes

Primary Outcomes

Rate of significant post-operative hypoparathyroidism (SPH) after total thyroidectomy (in %)

Time Frame: 6 months

Rate of significant post-operative hypoparathyroidism (SPH) after total thyroidectomy (in %)

Secondary Outcomes

  • Rate of inadvertent parathyroidectomy (in %)(within 4 weeks from operation)
  • Rate of parathyroid auto-transplantation (in %)(within operation)
  • Day 0 PTH(Post-operative Day 0)
  • Day 1 Post-operative serum parathyroid hormone levels (pmol/L)(Post-operative Day 1)
  • 3-month Post-operative serum parathyroid hormone levels (pmol/L)(Post-operative 3 months)
  • 6-month Post-operative serum parathyroid hormone levels (pmol/L)(Post-operative 6 months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Man Him Matrix Fung

Clinical Assistant Professor

The University of Hong Kong

Study Sites (1)

Loading locations...

Similar Trials